首页>投融资
Century Therapeutics
上市后再融资
Century Therapeutics Inc is founded in 2018 by Versant Ventures and Fujifilm Cellular Dynamics, focused on the development of allogeneic or off-the-shelf immune cell therapies for the treatment of hematologic and solid malignancies.In June 2020, Century Therapeutics had completed the acquisition of Empirica Therapeutics forming it as a subsidiary known as Century Therapeutics Canada, based in Hamilton, Ontario.By June 2019, Bayer AG had acquired a 28% interest in Century Therapeutics in through 'Leaps by Bayer', Bayer's innovation and collaboration model; at that time, Bayer committed US$215 million in investment,.In June 2021, Century Therapeutics had closed its initial public offering of 12,132,500 shares of its common stock at $20.00 per share.In June 2021, Century Therapeutics had announced the pricing of its initial public offering of 10,550,000 shares of its common stock at $20.00 per share. Later that month, the company raised $211 million by offeri
基本信息
-
公司全称Century Therapeutics Inc
-
类型变革性异体细胞疗法开发商
-
产业领域医药研发/制造、化学&生物药
-
公司人数15~50人
-
地址3675 Market St PHILADELPHIA PENNSYLVANIA 19104; US; Telephone: +12159814000;
-
联系电话215-981-4000
-
邮箱
-
成立时间2018-01-01
投融资
-
2024-04-11上市后再融资6000万美元Superstring Capital八方资本Adage Capital Partners LPBain CapitalDafna Capital ManagementVenrock CapitalBoxer CapitalCasdin Capital
-
2022-01-10上市后再融资1.5亿美元百时美施贵宝
-
2021-06-17上市2.11亿美元未透露
-
2021-03-03C轮1.6亿美元Logos CapitalCasdin CapitalMarshall WaceRA Capital奥博资本Qatar Investment AuthorityVersant VenturesAvidity Partners富达国际Leaps by Bayer八方资本Federated Hermes Kauffmann Funds
-
2019-07-01A轮2.5亿美元Fujifilm HoldingsLeaps by BayerVersant Ventures
- 加载更多
相关投融资企业
增发
AEON Biopharma, Inc.于2012年2月在特拉华州注册成立。他们是一家处于临床阶段的生物制药公司，专注于开发专有肉毒毒素复合物ABP-450（prabotulinumtoxinA）注射液，即ABP-450，用于使人衰弱的医疗状况，最初的重点是神经科学市场。他们最近完成了ABP-450治疗颈肌张力障碍的2期研究，并正在进行ABP-450治疗慢性和发作性偏头痛的2期研究。ABP-450是同一肉毒毒素复合体，目前被Evolus批准并以Jeuveau的名义销售用于美容适应症。他们拥有ABP-450治疗适应症在美国、加拿大、欧洲联盟、联合王国和某些其他国际领土的独家开发和分销权。他们建立了一支经验丰富的管理团队，在生物制药和肉毒毒素的开发和商业化方面拥有具体经验。
A+轮
妙顺（上海）生物科技有限公司是一家致力于医药产业领域，集研发、 生产与销售于一体的高新技术企业。 公司自2014年创立以来专注于民族品牌细胞模型的研发和制备，通过打造The Primary Cell Solution—TPCS自主研发品牌，开展进口替代工作打破美欧发达国家对细胞技术和中国市场的垄断，TPCS®旨在解决我国生物医药产业链上游的“卡脖子”环节，为国内创新药物研发产业赋能。
种子轮
General Proximity是一家突破性的生物技术平台公司，打算开发激活现有细胞机制的药物。该公司生产下一代诱导接近药物，使医生能够治疗有害的人类疾病。
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息